

Friday, December 8, 2017

1:05 PM-2:25 PM Scientific Workshop

Location: Georgia World Congress Center, Bldg. B, Level 4, B404

[New Findings from Population Studies of B-Cell Lymphoma and Leukemia](#)

Jeffrey Switchenko, PhD

2:25 PM-2:35 PM Scientific Workshop

Location: Georgia World Congress Center, Bldg. B, Level 4, B404

[Next Steps for B-Cell Neoplasms Epidemiology: Towards Translation](#)

Jeffrey Switchenko, PhD (panelist)

5:10 PM-5:55 PM Scientific Workshop

Location: Georgia World Congress Center, Bldg. B, Level 2, B211-B212

[Point-Counter Point: Prophylactic Transplantation for Leukemia Predisposition Syndromes](#)

Christopher Porter, MD

Saturday, December 9, 2017

7:30 AM-9:00 AM Scientific Program Presentation

Location: Georgia World Congress Center, Bldg. C, Level 3, Georgia BR 1-3

[Protein Homeostasis: A Key Target in Myeloma](#)

Number SCI-8 | Lawrence Boise, PhD

7:30 AM-9:00 AM Scientific Program Presentation

Location: Georgia World Congress Center, Bldg. B, Level 2, B206

[Thrombosis-on-a-Chip: A New Way to Model a Complex Process](#)

Number SCI-10 | Wilbur Lam, PhD

9:30 AM-11:00 AM Scientific Program Presentation

Location: Georgia World Congress Center, Bldg. B, Level 5, Murphy BR 1-2

[T-Cell Memory and Exhaustion](#)

Number SCI-34 | Rafi Ahmed, PhD

11:15 AM-12:15 PM Career Development Session

Location: Omni Hotel at CNN Center, International Ballroom F North Tower M2

[Medical Educators in Hematology](#)

Presenter: Kristi Blum, MD

4:00 PM-5:30 PM Scientific Program Presentation

Location: Georgia World Congress Center, Bldg. B, Level 5, Murphy BR 3-4

[Protein Homeostasis: A Key Target in Myeloma](#)

Number SCI-8 | Lawrence Boise, PhD

5:30 PM-7:30 PM Abstracts

Location: Georgia World Congress Center, Bldg. A, Level 1, Hall A2

[Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients \(pts\) with Relapsed Multiple Myeloma \(MMY1001\): An Open-Label, Phase 1b Study](#)

Abstract 1869 | Sagar Lonial, MD

[Clinical Characteristics and Outcomes of Myeloma Patients Exhibiting Translocation \(14;16\): An Ultra-High-Risk Group of Myeloma Patients](#)

Abstract 1822 | Anjay Nooka, MD, MPH

[Impact of Post-Transplant Lymphoproliferative Disorder Subtype on Survival](#)

Abstract 1578 | Jean Koff, MD

[Hierarchical Differences in Defensin Gene Expression in Plasmacytoid Dendritic Cells and Progenitor Cells from Five Different Hematopoietic Stem Cell Transplant Graft Types](#)

Abstract 1924 | Cynthia Giver, PhD

[High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations](#)

Abstract 1780 | Benjamin Barwick, PhD

[Efficacy of Early Post-Transplant Vaccination Using a Prime and Boost Strategy Is Independent of a Prior History of GvHD: Results from BMT CTN 0201](#)

Abstract 1972 | Edmund K. Waller, MD, PhD

Sunday, December 10, 2017

7:30 AM-9:00 AM Scientific Program Presentation

Location: Georgia World Congress Center, Bldg. B, Level 2, Hall B211-B212

[Thrombosis-on-a-Chip: A New Way to Model a Complex Process](#)

Number SCI-10 | Wilbur Lam, PhD

9:30 AM-11:00 AM Scientific Program Presentation

Location: Georgia World Congress Center, Bldg. B, Level 5, Murphy BR 1-2

[T-Cell Memory and Exhaustion](#)

Number SCI-34 | Rafi Ahmed, PhD

11:15 AM-12:15 PM Training Didactic Session

Location: Georgia World Congress Center, Bldg. B, Level 2, Hall B211-B212

[Time Management and Balance: Adult/ Clinical](#)

Presenter: Jean Koff, MD

2:00 PM-3:00 PM Oral Presentation

Location: Georgia World Congress Center, Bldg. B, Level 2, Hall B207-B208

[HLA-DRB1-Peptide Binding Prediction and Risk of Inhibitor Development in Non-Severe Hemophilia a](#)

Abstract 177 | Session 322 | Christine Kempton, MD, MSc

6:00 PM-8:00 PM Abstracts

Location: Georgia World Congress Center, Bldg. A, Level 1, Hall A2

[Optimization of Ex Vivo Activation and Expansion of T Cells for Therapy of Lymphoma Via Antagonism of PI3K \$\delta\$ and Vasoactive Intestinal Peptide Signaling](#)

Abstract 3195 | Edmund K. Waller, MD, PhD

[Intratatumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab](#)

Abstract 2771 | Christopher R. Flowers, MD, MS

[Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t\(11;14\) Relapsed/Refractory Multiple Myeloma](#)

Abstract 3131 | Jonathan Kaufman, MD

[A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma](#)

Abstract 3073 | Vikas Gupta, MD, PhD

[Predicting Venetoclax Sensitivity in Multiple Myeloma Using Biologic Activity Assays](#)

Abstract 3056 | Shannon Matulis, PhD

[Evaluation of Efficacy Outcomes Among Relapsed/Refractory Multiple Myeloma Treated Patients in a Real-World Setting](#)

Abstract 3093 | Ajay Nooka, MD, MPH

[Comparison of Overall Survival Associated with Lenalidomide + Dexamethasone and Bortezomib + Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations](#)

Abstract 3094 | Ajay Nooka, MD, MPH

Monday, December 11, 2017

10:30 AM-12:00 PM Oral Presentation

Location: Georgia World Congress Center, Bldg. A, Level 4, Marcus Auditorium

[Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study](#)

Abstract 650 | Session 624 | Jonathon Cohen, MD, MS